DALLAS, Sept. 23, 2009 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring oncology therapeutics developer BSD Medical Corp. (Nasdaq:BSDM - News). The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.

The investment report on BSD Medical Corp. (Nasdaq:BSDM - News) should be of particular interest to other biotechnology companies: AngioDynamics Inc. (Nasdaq:ANGO - News), Boston Scientific Corp. (NYSE:BSX - News), Intuitive Surgical Inc. (Nasdaq:ISRG - News) and Medtronic Inc. (NYSE:MDT - News).

It is available at: http://www.beaconequity.com/i/BSDM

Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity

BSD Medical Corp. (BSDM) develops, manufactures, markets and services systems developed to treat cancer and benign diseases using heat therapy derived from radio frequency and microwave energy. While the Company maintains its primary focus on developing products for the treatment of cancer, it is also engaged in making advances in the application of its technology for other therapies.

BSDM owns numerous domestic and foreign patents and patent licenses covering its current applications and products. The Company is also developing new technologies that may qualify for patent protection.

Message Board Search for BSDM: http://www.boardcentral.com/boards/BSDM

In the report, the analyst notes:

"Shares of BSDM were recently boosted after a recent study showed encouraging results of thermal treatment for cancer. According to the Company's press release, a German research study, which utilized the BSD-2000 Hyperthermia System, demonstrated that patients with high risk soft-tissue sarcomas were 30% more likely to be alive and cancer free almost three years after starting treatment ...

"In the U.S., BSDM's BSD-2000 Hyperthermia System is currently under investigational device restrictions. On September 18, the Company reported that U.S. Food and Drug Administration (FDA) continues its review of the Company's Humanitarian Device Exemption (HDE) marketing submission for its hyperthermia cancer treatment system."

To read the entire report visit: http://www.beaconequity.com/i/BSDM

BeaconEquity.com is one of the industry's largest small-cap report providers. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com

Beacon Equity Disclosure

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. BeaconEquity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.